Cortexyme, Inc.CRTXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

defenseworld.net

Sorrento Therapeutics (NASDAQ:SRNE) and Cortexyme (NASDAQ:CRTX) Head to Head Analysis

Institutional and Insider Ownership 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money

defenseworld.net

Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)

Valuation and Earnings This table compares Eloxx Pharmaceuticals and Cortexyme"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$36.06 million ($9.07) 0.00 Cortexyme N/A N/A -$89.94 million ($2.97) -1.20 Cortexyme is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals,

defenseworld.net

Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast

Insider and Institutional Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money

defenseworld.net

Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey

Institutional and Insider Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and

defenseworld.net

Cortexyme (NASDAQ:CRTX) vs. Prime Medicine (NYSE:PRME) Critical Review

Prime Medicine (NYSE: PRME - Get Free Report) and Cortexyme (NASDAQ: CRTX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations. Profitability This table compares Prime Medicine and Cortexyme's

defenseworld.net

Cortexyme (NASDAQ:CRTX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

Cortexyme, Inc. (NASDAQ: CRTX - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.54 and traded as high as $1.95. Cortexyme shares last traded at $1.91, with a volume of 382,771 shares changing hands. Cortexyme Trading Up 6.1% The firm has

investorplace.com

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today

Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on InvestorPlace.

benzinga.com

Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis

Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.

seekingalpha.com

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.

zacks.com

Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com

After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)

The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI

investorplace.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance